Foghorn Therapeutics

FDA Presses Pause on Another Foghorn Program
FDA Presses Pause on Another Foghorn Program
BioSpace
Foghorn Therapeutics
FDA
FHD-609
QTc
Flag link:
Foghorn sounds another warning about the class of ‘20
Foghorn sounds another warning about the class of ‘20
EP Vantage
Foghorn Therapeutics
IPOs
COVID-19
pandemic
biotech
Flag link:
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
Flag link:
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
Benzinga
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death
Flag link:
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
PR Newswire
Eli Lilly
Foghorn Therapeutics
oncology
Flag link:
Foghorn hits Nasdaq in $120M debut as the biotech IPO boom shows no sign of slowing
Foghorn hits Nasdaq in $120M debut as the biotech IPO boom shows no sign of slowing
Endpoints
Foghorn Therapeutics
IPOs
NASDAQ
chromatin regulatory system
Flag link:
Foghorn blows its klaxon, gunning for a $100M IPO hot on the heels of its Merck deal
Foghorn blows its klaxon, gunning for a $100M IPO hot on the heels of its Merck deal
Fierce Biotech
Foghorn Therapeutics
IPOs
Merck
chromatin regulatory system
Flag link:
Merck teams up with cancer startup Foghorn in $425M deal
Merck teams up with cancer startup Foghorn in $425M deal
Fierce Biotech
Merck
Foghorn Therapeutics
cancer
drug development
Flag link: